Immunohistochemical Markers Defined by Monoclonal Antibodies and Response to Bacillus Calmette-Guérin Endovesical Immunotherapy for Superficial Bladder Tumors

Flam, T.; Chopin, Dominique; Leleu, C; Abbou, Claude C.; Steg, A; Desligneres, S; Boccon‐Gibod, Liliane

doi:10.1159/000464076

Cited by 6 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Flam et al [8] investigated the relevance of an immunohistochemical loss of CK 18 expression on tumor recurrence and tumor progression in superficial tumors but failed to show any significance. Zlotta et al [54] found alterations of Ki-67 and p21WAF1/CIP1 expression to be correlated with tumor recurrence after BCG therapy.…”

Section: Response To Treatmentmentioning

confidence: 99%

Molecular pathology of non-invasive urothelial carcinomas (part I)

Helpap

Schmitz‐Dräger

Hamilton³

et al. 2003

Virchows Arch

View full text Add to dashboard Cite

An international consultation on the diagnosis of non-invasive urothelial neoplasms was held in Ancona, Italy in May 2001. Besides histology and problems of classification, one group of experts (Committee no. 3) discussed the molecular pathology and cytometry of noninvasive urothelial carcinomas. In the following first part, special immunohistochemical and molecular markers for stratifications in bladder cancer were discussed including different cytokeratins (clone 34bE12, CK 20), cell proliferation markers (Ki67/MIB-1, PCNA, AgNOR, DNA-cytometry), tumor suppressor genes and oncogenes (p53, p21, erb-B2, bcl-2), different receptor expressions of epidermal growth factor and vascular endothelial growth factor and others. These molecular markers were analyzed in diagnosis of urothelial carcinomas, recurrences, progression and response to treatment.

show abstract

Section: Response To Treatmentmentioning

confidence: 99%

Molecular pathology of non-invasive urothelial carcinomas (part I)

Helpap

Schmitz‐Dräger

Hamilton³

et al. 2003

Virchows Arch

View full text Add to dashboard Cite

show abstract

On the mode of action of intravesical bacillus Calmette-Gu�rin: in vitro characterization of BCG-activated killer cells

Böhle¹,

Thanhäuser²,

Ulmer

et al. 1994

Urol. Res.

View full text Add to dashboard Cite

Previously we had shown that, upon activation with viable bacillus Calmette-Guérin (BCG), peripheral blood mononuclear cells (PBMNC) could be rendered cytotoxic against otherwise insensitive natural killer (NK)-resistant bladder cancer cell lines. This phenomenon had been termed the BCG-activated killer (BAK) cell phenomenon. By means of depletion and enrichment procedures of mononuclear cell subpopulations derived from BCG-activated PBMNC we further characterized the cytolytic BAK effector cells functionally in an in vitro cytotoxicity assay against the bladder carcinoma cell line BT-A and phenotypically in their pathway of activation. Neither macrophages nor CD4+ T-helper/inducer cells exerted cytotoxic BAK activity. This cytotoxicity was restricted to the CD8+CD56+ subpopulation of T-cytotoxic/NK cells. Furthermore, activation of BAK cells via interferon gamma (IFN-gamma) was evidenced by the complete inhibition of BAK cell generation with an IFN-gamma antibody.

show abstract